A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.

Article Details

Citation

Copy to clipboard

van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ

A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.

Br J Clin Pharmacol. 2002 Jun;53(6):644-7.

PubMed ID

12047490 [ View in PubMed

]

Abstract

AIMS: To compare the effects of nabumetone and meloxicam, two cyclo-oxygenase-2 (COX-2) preferential nonsteroidal anti-inflammatory drugs (NSAIDs), on platelet COX-1 activity and platelet function. METHODS: Twelve healthy volunteers (3 male, 9 female, median age 22 years) participated in an open, randomized, cross-over trial of nabumetone 1000 mg twice daily vs meloxicam 7.5 mg twice daily during 1 week with 2 weeks wash-out. After a second 2 week wash-out period, one dose of indomethacin 50 mg was given as a positive control to check for NSAID induced inhibition of platelet function. COX-1 inhibition was measured as percentage inhibition of serum TXB2 generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100. Data are reported as median with range. Paired variables were analysed using Wilcoxons signed rank test. RESULTS: TXB2 levels decreased significantly after all three medications, but percentage inhibition after nabumetone and indomethacin (88% and 97%, respectively) was significantly higher than after meloxicam (63%) (P<0.05). Closure times increased significantly after administration of all three medications (P<0.05). Increases in closure time after administration did not differ between nabumetone and meloxicam (24% and 14%, respectively), but were significantly larger after indomethacin administration (63%) (P<0.01). CONCLUSIONS: In the maximum registered dosage, nabumetone inhibits thromboxane production much more than meloxicam, signifying less COX-2 selectivity of the former. However, both nabumetone and meloxicam cause only minor impairment in platelet function in comparison with indomethacin and the difference between them is not significant.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Nabumetone	Prostaglandin G/H synthase 2	Protein	Humans	Yes	Inhibitor	Details

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Meloxicam	Approved Vet Approved	Thromboxane B2	decreased	Meloxicam decreases the level of Thromboxane B2 in the blood
Nabumetone	Approved	Thromboxane B2	decreased	Nabumetone decreases the level of Thromboxane B2 in the blood
Indomethacin	Approved Investigational	Thromboxane B2	decreased	Indomethacin decreases the level of Thromboxane B2 in the blood